Eli Lilly to build $6.5bn orforglipron production site in Texas

Eli Lilly has revealed it is to build an active pharmaceutical product (API) facility in Texas, US, a week after revealing Virginia as the first site in its $27bn US manufacturing drive. The $6.5bn manufacturing facility will produce Eli Lilly’s array of small molecule therapeutics – chief among which will be orforglipron, the drugmaker’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) hopeful in obesity treatment. Lilly’s CEO David Ricks said: "Our new Houston site will enhance Lilly's ability t ...